Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 20/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 19/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 19/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 19/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 17/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 17/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 17/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 17/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 17/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 17/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 17/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2143881 | 0.76 | HDAC3 (0.40) | HDAC6HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL1367540 | 0.65 | HDAC1 (0.41) | HDAC6HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL17992025 | 0.64 | HDAC1 (0.41) | HDAC6HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL16330248 | 0.64 | HDAC1 (0.41) | HDAC6HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL1366117 | 0.64 | HDAC1 (0.45) | HDAC6HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL3811028 | 0.63 | HDAC1 (0.41) | HDAC6HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL15832596 | 0.63 | CHRNA7 (0.56) | HDAC6HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL4308547 | 0.62 | HDAC3 (0.44) | HDAC6HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL8009252 | 0.61 | HDAC1 (0.50) | HDAC6HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL16566468 | 0.61 | HDAC1 (0.50) | HDAC6HDAC3HDAC1HDAC2HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110288070-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | FMR LLC | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288070-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC5, HDAC2 | HDAC6 9/4885HDAC3 14/4885HDAC1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.